CReMEC

 

Oncodesign is involved in the "Medicen" Paris Biocluster, focused on therapeutic innovation, being the leader of the CReMEC project: a new resource center of experimental cancer models.

In addition to Oncodesign, this project includes the following partners:

• 3 pharmaceutical companies (Institut de Recherche Servier, Ipsen and sanofi-aventis)
• various French institutions (Public Assistance and Paris Hospitals, Curie Institute, Gustave Roussy Institute, Cochin Institute, University Paris VII, INSERM, CNRS…)

In order to improve preclinical research, this project aims to:

• Establish a single database of the animal models developed by the project's partners. This database will enable researchers to know where to find a specific model and the characteristics of this model.
• Create new rodent models from primary tumors or transgenic mice. The first developed indication will be colon tumors. This part of the CReMEC project involves surgical partners in three different clinical centres who will initiate the development of primary xenografted models which are more representative of human disease.
• Study the transplantation factors that are involved in the tumor take of human tumors xenografted in rodents.

This French Project represents a total budget of 5 million euros and aims to evolve as a European cluster of therapeutic innovation by 2010.